Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System
The agreement calls for Blue Ox to provide consulting services to Obalon, including helping Obalon to develop and implement an effective coverage and reimbursement-based go-to-market strategy. Activities will include an evaluation of the current clinical evidence of the Obalon Balloon System, consideration of health economic studies to define cost of care reductions for patients with diabetes and hypertension resulting from its use, and assessments and readying of strategies for successful commercialization with managed care companies and risk-based providers.
Obalon continued to reiterate that obtaining reimbursement is never certain and can take many years to achieve, and if achieved, may not be determinative of the Company’s success. If initial efforts with payers begin to bear success, Obalon would expect to need to raise additional capital to support those efforts.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended
Obalon Therapeutics, Inc.Investor Contact: Andrew RasdalPresident and Chief Executive Officer Obalon Therapeutics, Inc.Office: +1 844 362 2566 firstname.lastname@example.org
Source: Obalon Therapeutics, Inc.